Uncommon Therapeutics
PrivateLast Round
Seed
Feb 1, 2025
Total Funding Raised
$500,000
Company Overview
Uncommon Therapeutics is a biotechnology company that develops gene-based and multi-modal therapeutics for rare neurodevelopmental monogenic diseases, with an initial focus on Rett Syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Uncommon Therapeutics Comparables
Compare Uncommon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Unravel Biosciences | 76% | |
| Neurogene | 74% | |
| Taysha Gene Therapies | 70% |
Uncommon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 1, 2025 |
Uncommon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pioneer Fund | Seed |
| Ethos Fund | Seed |
| Singularity Capital | Seed |
| Y Combinator | Seed |
| Roar Ventures | Seed |
| Angel Operator Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 1, 2025
$500K raised from Angel Operator Partners, Ethos Fund, and others.
Uncommon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Uncommon Therapeutics's valuation, stock price, and market status.
Is Uncommon Therapeutics a public or private company?
Uncommon Therapeutics is a private company.
What is the current stock price of Uncommon Therapeutics?
Uncommon Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Uncommon Therapeutics worth (valuation)?
Valuation information for Uncommon Therapeutics is not publicly available.
Can I buy Uncommon Therapeutics stock?
Uncommon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Uncommon Therapeutics's last funding round?
Uncommon Therapeutics's most recent funding round was Seed on February 1, 2025.
Who are the main investors in Uncommon Therapeutics?
Key investors in Uncommon Therapeutics include Pioneer Fund, Ethos Fund, Singularity Capital, Y Combinator, Roar Ventures.
Will Uncommon Therapeutics IPO soon?
No public IPO plans have been announced for Uncommon Therapeutics.
How can I track Uncommon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Uncommon Therapeutics's secondary market activity and sign up for updates.